GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Revive Therapeutics Ltd (FRA:31R) » Definitions » Cyclically Adjusted Price-to-FCF

Revive Therapeutics (FRA:31R) Cyclically Adjusted Price-to-FCF : (As of Jun. 04, 2025)


View and export this data going back to 2017. Start your Free Trial

What is Revive Therapeutics Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Revive Therapeutics Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Revive Therapeutics's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revive Therapeutics Cyclically Adjusted Price-to-FCF Chart

Revive Therapeutics Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Revive Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Revive Therapeutics's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Revive Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Revive Therapeutics's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Revive Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Revive Therapeutics's Cyclically Adjusted Price-to-FCF falls into.


;
;

Revive Therapeutics Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Revive Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2024 is calculated as:

For example, Revive Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-0/127.3637*127.3637
=0.000

Current CPI (Dec. 2024) = 127.3637.

Revive Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201503 -0.010 99.789 -0.013
201506 -0.007 100.500 -0.009
201509 -0.020 100.421 -0.025
201512 -0.022 99.947 -0.028
201603 -0.007 101.054 -0.009
201606 -0.007 102.002 -0.009
201609 -0.011 101.765 -0.014
201612 -0.007 101.449 -0.009
201703 -0.008 102.634 -0.010
201706 -0.005 103.029 -0.006
201709 -0.005 103.345 -0.006
201712 -0.005 103.345 -0.006
201803 -0.004 105.004 -0.005
201806 -0.004 105.557 -0.005
201809 -0.003 105.636 -0.004
201812 -0.003 105.399 -0.004
201903 -0.002 106.979 -0.002
201906 -0.004 107.690 -0.005
201909 -0.002 107.611 -0.002
201912 -0.002 107.769 -0.002
202003 -0.006 107.927 -0.007
202006 -0.004 108.401 -0.005
202009 -0.003 108.164 -0.004
202012 -0.003 108.559 -0.004
202103 -0.008 110.298 -0.009
202106 -0.005 111.720 -0.006
202109 -0.004 112.905 -0.005
202112 -0.012 113.774 -0.013
202203 -0.009 117.646 -0.010
202206 -0.004 120.806 -0.004
202209 -0.006 120.648 -0.006
202212 -0.002 120.964 -0.002
202303 -0.004 122.702 -0.004
202306 -0.001 124.203 -0.001
202309 -0.001 125.230 -0.001
202312 -0.002 125.072 -0.002
202403 -0.003 126.258 -0.003
202406 0.000 127.522 0.000
202409 -0.001 127.285 -0.001
202412 0.000 127.364 0.000

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Revive Therapeutics  (FRA:31R) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Revive Therapeutics Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Revive Therapeutics's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Revive Therapeutics Business Description

Traded in Other Exchanges
Address
82 Richmond Street East, The Canadian Venture Building, Toronto, ON, CAN, M5C 1P1
Revive Therapeutics Ltd is focused on the research, development, and commercialization of novel psychedelic and cannabinoid-based life sciences products and drug repurposing for infectious diseases. The firm's technology is being developed to fill the medical needs for diseases and disorders such as pain, inflammation, and wound care. Currently, the Company is exploring the use of Bucillamine for the potential treatment of public health medical emergencies and rare inflammatory disorders. Revive is also advancing the development of Psilocybin-based therapeutics through various program.

Revive Therapeutics Headlines

No Headlines